Focused On-demand Library for Transcription initiation factor TFIID subunit 13

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q15543

UPID:

TAF13_HUMAN

Alternative names:

Transcription initiation factor TFIID 18 kDa subunit

Alternative UPACC:

Q15543; B2R5E5; Q5TYV6

Background:

Transcription initiation factor TFIID subunit 13, also known as the 18 kDa subunit, is integral to the TFIID basal transcription factor complex, crucial for the initiation of RNA polymerase II-dependent transcription. This complex, comprising TBP and various TAFs, is pivotal in promoter recognition, binding, and pre-initiation complex assembly. TAF13, alongside TAF11 and TBP, plays a significant role in promoter binding by TFIID and TFIIA transcription factor complexes.

Therapeutic significance:

Intellectual developmental disorder, autosomal recessive 60, characterized by mild intellectual disability and delayed psychomotor development, is linked to variants affecting the gene encoding TFIID subunit 13. Understanding the role of Transcription initiation factor TFIID subunit 13 could open doors to potential therapeutic strategies for this disorder.